Abstract:Alpha-synuclein is an intrinsically disordered protein that accumulates in the brains of patients with Parkinson's disease and forms intraneuronal inclusions called Lewy Bodies. While the mechanism underlying the dysregulation of alpha-synuclein in Parkinson's disease is unclear, it is thought that prionoid cell-to-cell propagation of alpha-synuclein has an important role. Through a high throughput screen, we recently identified 38 genes whose knock down modulates alpha-synuclein propagation. Follow up experiments were undertaken for two of those genes, TAX1BP1 and ADAMTS19, to study the mechanism with which they regulate alpha-synuclein homeostasis. We used a recently developed M17D neuroblastoma cell line expressing triple mutant (E35K+E46K+E61K) "3K" alpha-synuclein under doxycycline induction. 3K alpha-synuclein spontaneously forms inclusions that show ultrastructural similarities to Lewy Bodies. Experiments using that cell line showed that TAX1BP1 and ADAMTS19 regulate how alpha-synuclein interacts with lipids and phase separates into inclusions, respectively, adding to the growing body of evidence implicating those processes in Parkinson's disease. Through RNA sequencing, we identified several genes that are differentially expressed after knock-down of TAX1BP1 or ADAMTS19. Burden analysis revealed that those differentially expressed genes (DEGs) carry an increased frequency of rare risk variants in Parkinson's disease patients versus healthy controls, an effect that was independently replicated across two separate cohorts (GP2 and AMP-PD). Weighted gene co-expression network analysis (WGCNA) showed that the DEGs cluster within modules in regions of the brain that develop high degrees of alpha-synuclein pathology (basal ganglia, cortex). We propose a novel model for the genetic architecture of sporadic Parkinson's disease: increased burden of risk variants across genetic networks dysregulates pathways underlying alpha-synuclein homeostasis, thereby leading to pathology and neurodegeneration.

Unveiling the genes and pathways that are dysregulated in dopaminergic neurons during both familial and sporadic Parkinson’s disease

Key genes and convergent pathogenic mechanisms in Parkinson disease

Genetic Insights into Sporadic Parkinson's Disease Pathogenesis

Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies

Decoding the Role of Familial Parkinson’s Disease-Related Genes in DNA Damage and Repair

Revealing novel genes related to Parkinson's disease pathogenesis and establishing an associated model

Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease

Genetic Networks in Parkinson’s and Alzheimer’s Disease

Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease.

Synaptic dysfunction and extracellular matrix dysregulation in dopaminergic neurons from sporadic and E326K-GBA1 Parkinson’s disease patients

Druggable transcriptomic pathways revealed in Parkinson's patient-derived midbrain neurons

Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease

Multimodal Analysis of Gene Expression from Postmortem Brains and Blood Identifies Synaptic Vesicle Trafficking Genes to Be Associated with Parkinson's Disease.

Single-Cell RNA-Seq of Mouse Dopaminergic Neurons Informs Candidate Gene Selection for Sporadic Parkinson Disease

Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinson’s disease

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations

Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease.

Gene–environment Interactions: Key to Unraveling the Mystery of Parkinson's Disease

Parkinson disease: from pathology to molecular disease mechanisms

Identification of Hub Genes And Potential Molecular Mechanisms In Peripheral Blood Mononuclear Cells of Patients With Parkinson’s Disease